Billing and Coding: Intravenous Immune Globulin (IVIg)-NCD 250.3

CMS covers IVIg when the patient meets at least one of: failed conventional therapy, contraindication to conventional therapy, or rapidly progressive disease requiring temporary IVIg while awaiting effect of conventional agents. IVIg for autoimmune mucocutaneous blistering disease is limited to short-term use and not allowed as maintenance; specific definitions of 'failure,' 'contraindication,' and 'short-term' are determined by contractors.

"Patient has failed conventional therapy."

Sign up to see full coverage criteria, indications, and limitations.